Last updated: August 10, 2026
Trisenox, the branded arsenic trioxide injection, is a mature oncology product with durable clinical demand but limited standalone financial visibility. Its commercial trajectory is shaped by three forces: the shift toward arsenic trioxide plus all-trans retinoic acid (ATRA) in frontline acute promyelocytic leukemia (APL), generic injectable competition, and the absence of meaningful remaining regulatory exclusivity. Teva Pharmaceuticals owns the U.S. Trisenox business through its acquisition of Cephalon, which previously held the product rights.[1]
The drug remains clinically important because APL is highly responsive to arsenic trioxide. The commercial opportunity is constrained by the rarity of APL, short treatment duration for many patients, hospital procurement pressure, and generic substitution. Teva does not publicly disclose Trisenox revenue as a separate product line, so its exact financial trajectory cannot be calculated from company filings. The available evidence supports a mature-product assessment: stable or growing treatment demand, but declining brand share and pricing pressure.
What is Trisenox and how is it used?
Trisenox is an intravenous formulation of arsenic trioxide approved for acute promyelocytic leukemia. The active ingredient is arsenic trioxide, supplied as a sterile injection for dilution and intravenous administration.
FDA-approved indications
The FDA approved Trisenox in 2000 for patients with APL whose disease had relapsed or is refractory to prior retinoid therapy.[2] In 2013, the FDA expanded the indication to include newly diagnosed low- or intermediate-risk APL in combination with tretinoin, also known as ATRA.[2]
The product is used in:
- Induction of remission
- Consolidation therapy
- Relapsed or refractory APL
- Frontline treatment with ATRA for selected newly diagnosed patients
Clinical practice has shifted toward chemotherapy-free or chemotherapy-light ATRA-plus-arsenic regimens for many non-high-risk patients. That shift increases the strategic importance of arsenic trioxide while reducing the role of traditional anthracycline-based chemotherapy.[3]
Treatment duration and demand pattern
Trisenox demand is episodic rather than chronic. Patients typically receive daily or near-daily intravenous treatment during induction, followed by consolidation cycles. This produces concentrated hospital utilization and makes procurement contracts, vial utilization, wastage, and infusion-center capacity important commercial variables.
APL is rare. U.S. incidence estimates generally place the disease at approximately 600 to 700 new cases annually, although estimates vary by source and methodology.[4] The limited patient population caps volume growth even when treatment guidelines favor arsenic trioxide.
When did Trisenox lose exclusivity?
Trisenox’s principal U.S. market exclusivity has expired. The product was approved in 2000, and the original orphan-drug exclusivity period ended in 2007. The 2013 supplemental approval for newly diagnosed APL generated a separate regulatory exclusivity period, but that period has also expired.
| Milestone |
Date |
Commercial effect |
| Original FDA approval for relapsed/refractory APL |
2000 |
Established the branded market |
| Orphan-drug exclusivity for original indication |
2000-2007 |
Blocked approval of the same drug for the same indication |
| FDA approval for newly diagnosed low/intermediate-risk APL with ATRA |
2013 |
Expanded addressable use |
| Supplemental approval exclusivity period |
Expired |
No current protection from that approval |
| Generic arsenic trioxide competition |
Post-exclusivity period |
Reduced brand pricing and share |
FDA regulatory exclusivity is separate from patent protection. Trisenox’s commercial protection was not based on a long-duration composition-of-matter patent comparable to those supporting many small-molecule products. The active ingredient, arsenic trioxide, is an old chemical entity, and the current market is primarily exposed to formulation, manufacturing, regulatory, and contracting barriers.
What patents protect Trisenox?
No commercially significant, long-lived patent barrier is apparent for the core arsenic trioxide active ingredient. The relevant IP questions concern the finished injectable formulation, manufacturing processes, dosing methods, and possible use claims rather than ownership of arsenic trioxide itself.
Orange Book status
Trisenox is an FDA-approved injectable drug listed in FDA product databases. Its current competitive position does not depend on an active composition patent or unexpired orphan exclusivity. Orange Book-listed patent coverage, if present for a specific presentation or use, would need to be evaluated against the product’s current listing and patent-status entries rather than inferred from the original approval date.[5]
The practical conclusion is that a prospective generic applicant would not face the type of fundamental active-ingredient patent risk seen with patented oncology medicines. The principal pathway would be an abbreviated new drug application, subject to the FDA’s requirements for injectable products and pharmaceutical equivalence.
What formulations are protected by Trisenox-related patents?
The commercial product is an aqueous injectable solution. Potentially protectable elements can include:
- Concentration and excipient selection
- Container-closure systems
- Sterility and particulate control
- Stability over the labeled shelf life
- Dilution and administration procedures
- Manufacturing controls for a toxic inorganic active ingredient
These features can raise development costs, but they generally do not prevent competition after the relevant regulatory and patent barriers expire. Formulation differences may support product differentiation, yet they do not create a durable moat unless tied to enforceable claims with meaningful remaining patent life.
Are method-of-use patents a major Trisenox risk?
Method-of-use protection is limited because the principal clinical use, APL treatment, is well established. A patent covering a specific dosing schedule, combination regimen, patient subgroup, or treatment sequence could create narrow legal exposure, but it would not normally block all generic use of arsenic trioxide.
A generic applicant may seek a Paragraph IV certification against any listed method-of-use patent or use a section viii statement to omit a patented indication from its labeling. The commercial effect depends on whether the protected use is clinically material and whether physicians can prescribe the generic for nonprotected indications.
How strong is the Trisenox patent estate?
The Trisenox patent estate is weak relative to newer oncology products with active composition, formulation, and biomarker patents.
| Patent-estate factor |
Assessment |
| Active ingredient |
Weak; arsenic trioxide is an old compound |
| Original orphan exclusivity |
Expired |
| New indication exclusivity |
Expired |
| Core formulation barrier |
Limited and potentially design-aroundable |
| Method-of-use protection |
Potentially narrow |
| Manufacturing know-how |
Relevant but difficult to enforce against approved competitors |
| Regulatory complexity |
Moderate for sterile injectable products |
| Overall patent strength |
Low to moderate, with manufacturing and quality controls more important than patents |
The product’s remaining defensibility comes from supply reliability, hospital contracts, safety systems, regulatory history, and manufacturing execution. Those advantages can preserve sales after patent expiry but do not justify a premium comparable to an actively protected branded oncology therapy.
Which companies are challenging Trisenox?
The competitive threat comes primarily from generic arsenic trioxide manufacturers and suppliers of hospital-administered oncology injectables. The relevant competitors may include companies with approved or marketed arsenic trioxide injection products, contract manufacturers, and distributors supplying hospitals through group purchasing organizations.
The market is not characterized by a single direct rival with a differentiated mechanism. Competition is more likely to develop through:
- FDA-approved generic arsenic trioxide injection.
- Hospital contract pricing and formulary substitution.
- Alternative package sizes or vial configurations.
- Reliable supply during oncology-drug shortages.
- Distributor and group-purchasing organization relationships.
The number of effective competitors can be lower than the number of approved products. Sterile injectable manufacturing has higher technical and compliance requirements than oral solid-dose manufacturing. A limited supplier base can support periods of pricing stability even when formal exclusivity has ended.
What is the FDA regulatory status of Trisenox?
Trisenox remains an FDA-approved prescription oncology product for APL. The label contains important warnings concerning differentiation syndrome, QT-interval prolongation, electrolyte abnormalities, hepatotoxicity, and cardiac monitoring.[2]
Regulatory requirements affecting competition
A competing injectable must establish pharmaceutical equivalence and meet FDA requirements for:
- Sterility
- Strength and concentration
- Container closure
- Impurities and degradation products
- Stability
- Manufacturing controls
- Labeling and administration instructions
Arsenic trioxide also creates occupational and handling requirements. Manufacturing facilities must control exposure to a toxic active ingredient and maintain appropriate environmental, worker-safety, and quality systems. These requirements increase operational complexity but are not equivalent to patent exclusivity.
Biosimilar risk
Biosimilar risk is not relevant to Trisenox. Arsenic trioxide is a chemically defined small molecule, not a biologic. Competition proceeds through generic-drug pathways rather than the FDA biosimilar pathway under section 351(k) of the Public Health Service Act.
What is the generic launch risk for Trisenox?
Generic launch risk is high because the principal exclusivity periods have expired and the product has a relatively simple active ingredient. The timing and impact of generic entry depend on FDA approval status, commercial supply, hospital contracts, and the number of manufacturers willing to support a small oncology market.
Generic launch scenarios
| Scenario |
Expected effect on Trisenox |
| One effective generic supplier |
Moderate price pressure; brand may retain some hospital accounts |
| Two or more reliable generic suppliers |
High erosion in price and unit share |
| Generic supply interruption |
Temporary recovery in brand demand or pricing |
| Hospital-mandated substitution |
Rapid loss of branded volume |
| Continued physician preference for established product |
Slower erosion, especially in complex induction protocols |
The product’s parenteral route can delay or limit competition compared with oral drugs because sterile manufacturing is costly and quality failures can remove suppliers from the market. That factor supports a more gradual erosion curve, but it does not restore exclusivity.
What patent litigation affects Trisenox?
No major, publicly established patent litigation has defined the current Trisenox market in the manner seen with blockbuster oncology products. The key legal exposure is potential Paragraph IV litigation involving listed formulation or method-of-use patents, if any remain relevant to an asserted generic filing.
A Paragraph IV dispute would likely focus on:
- Whether a listed patent claims the approved injectable formulation
- Whether the patent covers an indication that a generic seeks to label
- Whether the patent is valid and enforceable
- Whether the generic product has an equivalent formulation
- Whether a carve-out can avoid infringement
Because the core active ingredient is old and the product has no apparent current composition patent barrier, litigation risk is more likely to be narrow and tactical than market-wide.
How does Trisenox compare with competing APL treatments?
Trisenox competes clinically with ATRA, chemotherapy, and other arsenic trioxide products rather than with a single replacement drug.
| Treatment |
Role in APL |
Commercial effect on Trisenox |
| Arsenic trioxide plus ATRA |
Preferred approach for many non-high-risk patients |
Supports underlying arsenic demand |
| ATRA plus chemotherapy |
Used in selected higher-risk or institution-specific settings |
Limits arsenic use in some populations |
| Generic arsenic trioxide |
Direct product competition |
Pressures price and brand share |
| Injectable chemotherapy regimens |
Alternative treatment architecture |
Can reduce arsenic utilization in selected patients |
| Clinical-trial regimens |
Limited segment |
Small impact on total demand |
The shift from chemotherapy-based treatment to ATRA-plus-arsenic is favorable for the therapeutic class. The benefit accrues to arsenic trioxide as a molecule, not necessarily to Trisenox as a brand.
What is the financial trajectory of Trisenox?
Teva reports product and geographic revenue at an aggregate level and does not provide a recurring standalone Trisenox revenue series in its annual reports.[1] A precise product-level revenue forecast therefore cannot be derived from public filings.
The likely financial trajectory has four phases:
1. Specialty-product establishment
After the 2000 approval, Trisenox built a specialty oncology market based on orphan-disease demand and limited treatment alternatives. The product benefited from physician familiarity and regulatory recognition.
2. Indication expansion
The 2013 approval for newly diagnosed low- and intermediate-risk APL expanded the commercial opportunity. ATRA-plus-arsenic protocols increased the drug’s relevance in first-line treatment, particularly as clinical evidence supported chemotherapy-free management for many patients.[2][3]
3. Loss of exclusivity
Expiration of orphan and supplemental exclusivity opened the market to generic competition. The primary economic impact is likely lower net price and lower branded unit share rather than a collapse in total arsenic trioxide demand.
4. Mature injectable-product economics
The product now operates as a mature hospital injectable. Revenue depends on:
- Number of diagnosed APL patients
- Share of patients receiving arsenic-based regimens
- Brand versus generic utilization
- Contract pricing
- Vial wastage
- Supply continuity
- Hospital reimbursement and budget pressure
For Teva, Trisenox is strategically more relevant as part of its specialty and hospital portfolio than as a separately disclosed growth driver. The product is unlikely to materially alter Teva’s consolidated financial outlook. Teva reported total revenue of approximately $15.8 billion in 2023, but its filings do not isolate Trisenox sales.[1]
What licensing deals affect Trisenox?
The key historical transaction was Cephalon’s licensing and commercialization relationship for Trisenox, followed by Teva’s acquisition of Cephalon in 2011.[6] That transaction transferred Trisenox into Teva’s specialty-pharmaceutical portfolio.
The current commercial question is not whether a new license unlocks a protected market. It is whether Teva retains sufficient manufacturing, distribution, and hospital-contract advantages to sustain branded economics against generic arsenic trioxide. No major recent licensing transaction is required to explain the product’s current market position.
What manufacturing and IP barriers protect Trisenox?
Manufacturing barriers are more meaningful than patent barriers. Arsenic trioxide injection requires controlled production of a toxic active ingredient in a sterile injectable environment. Relevant barriers include:
- Validated aseptic processing
- Control of elemental and organic impurities
- Container-closure integrity
- Stability and degradation monitoring
- Toxic-substance handling
- Specialized worker-protection procedures
- FDA inspection readiness
- Reliable supply of injectable components
These barriers can reduce the number of effective competitors and create temporary pricing support. They also expose the product to shortage risk if a manufacturer experiences a quality event, facility shutdown, or supply-chain disruption.
Geographically, the competitive environment differs by jurisdiction. The United States relies on FDA-approved products and hospital procurement systems. Europe and other markets apply separate marketing-authorisation and tender frameworks. A product may retain stronger commercial positioning in a market with limited approved suppliers even after U.S. generic entry.
What generic entry risks exist for Trisenox investors and licensees?
The principal risks are commercial, not patent-based.
High-probability risks
- Rapid substitution by lower-priced generic arsenic trioxide
- Hospital tender losses
- Net-price compression
- Reduced brand utilization in frontline APL
- Loss of bargaining power with distributors
- Greater dependence on supply reliability
Moderating factors
- Small patient population
- Sterile injectable manufacturing requirements
- Potentially limited effective suppliers
- Established physician experience with the branded product
- Temporary shortages among generic competitors
- High clinical consequences of treatment interruption
The most likely outcome is a gradual-to-rapid erosion pattern after reliable generic supply is established, with intermittent brand resilience during shortages or in institutions that prioritize established suppliers.
Key Takeaways
- Trisenox is an FDA-approved arsenic trioxide injection for acute promyelocytic leukemia.
- Its original and supplemental regulatory exclusivities have expired.
- The active ingredient is old, so the core patent estate is weak compared with newer oncology drugs.
- Generic competition is the principal threat to branded revenue.
- ATRA-plus-arsenic treatment adoption supports molecule-level demand but does not protect the Trisenox brand.
- Sterile injectable manufacturing, toxicity controls, and supply reliability are more important than patents in the current market.
- Teva does not disclose standalone Trisenox revenue, preventing a precise product-level financial model.
- The commercial outlook is consistent with a mature specialty injectable: stable clinical relevance, limited volume growth, and sustained pricing pressure.
FAQs About Trisenox Market and Exclusivity
Is Trisenox still protected by orphan-drug exclusivity?
No. The original orphan-drug exclusivity period expired, and the later supplemental indication exclusivity has also expired.
Is arsenic trioxide a biologic requiring biosimilar approval?
No. Arsenic trioxide is a chemically defined small molecule. Competing products use the FDA generic-drug pathway rather than the biosimilar pathway.
Can a generic company launch arsenic trioxide without challenging a method-of-use patent?
Yes. A generic applicant may use a section viii labeling carve-out for a patented indication when legally and regulatorily appropriate, or it may certify against listed patents under the abbreviated new drug application process.
Does ATRA-plus-arsenic treatment increase Trisenox revenue?
It increases demand for arsenic trioxide in eligible APL patients, but generic substitution determines how much of that demand accrues to Trisenox.
Is Trisenox material to Teva’s consolidated revenue?
Trisenox is not separately disclosed in Teva’s public financial reporting. Given Teva’s multibillion-dollar consolidated revenue base, it is unlikely to be a major company-wide revenue driver, although it remains relevant within specialty oncology.
References
- Teva Pharmaceutical Industries Ltd. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Trisenox (arsenic trioxide) injection prescribing information.
- National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Acute myeloid leukemia.
- American Cancer Society. (2024). Acute promyelocytic leukemia statistics and overview.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Teva Pharmaceutical Industries Ltd. (2011). Teva completes acquisition of Cephalon.
